Furthermore, in pancreatic tumors treated with both a lysyl oxidase inhibitor and immune therapy, a decrease in pro-tumorigenic TAMs and an increase in CD8+ Granzyme B+ T-cells (anti-tumorigenic) was associated with increased survival [125]. Here, LOX is linked to pancreatic neoplasm.